Frontier Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Frontier Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.75M	Sell	29,056 -1,548	-5%	-$467K	0.08%	261
2026 Q1	$10.1M	Sell	30,604 -18,255	-37%	-$6.21M	0.1%	236
2025 Q4	$19.4M	Sell	48,859 -70,019	-59%	-$31M	0.21%	170
2025 Q3	$54.2M	Buy	118,878 +15,875	+15%	+$6.46M	0.49%	64
2025 Q2	$33.6M	Buy	103,003 +583	+0.6%	+$161K	0.31%	133
2025 Q1	$27.7M	Sell	102,420 -2,298	-2%	-$591K	0.3%	126
2024 Q4	$24.6M	Sell	104,718 -6,513	-6%	-$1.71M	0.23%	155
2024 Q3	$30.6M	Sell	111,231 -57,211	-34%	-$14.9M	0.29%	139
2024 Q2	$40.9M	Buy	+168,442	New	+$26.6M	0.41%	97
2021 Q3	–	Sell	-45,822	Closed	-$7.77M	–	282
2021 Q2	$7.77M	Buy	+45,822	New	+$6.71M	0.06%	249
2021 Q1	–	Sell	-4,746	Closed	-$617K	–	278
2020 Q4	$617K	Hold	4,746	–	–	﹤0.01%	281
2020 Q3	$691K	Sell	4,746 -104	-2%	-$14.8K	0.01%	287
2020 Q2	$718K	Sell	4,850 -34,187	-88%	-$4.61M	0.01%	289
2020 Q1	$4.25M	Sell	39,037 -12,447	-24%	-$1.44M	0.05%	245
2019 Q4	$5.93M	Sell	51,484 -41,885	-45%	-$4.18M	0.04%	245
2019 Q3	$7.51M	Buy	93,369 +18,680	+25%	+$1.48M	0.06%	240
2019 Q2	$5.42M	Buy	74,689 +6,563	+10%	+$504K	0.04%	256
2019 Q1	$6.37M	Sell	68,126 -129,743	-66%	-$10.9M	0.05%	254
2018 Q4	$14.4M	Buy	197,869 +191,629	+3,071%	+$14.7M	0.12%	204
2018 Q3	$546K	Sell	6,240 -29,960	-83%	-$3.01M	﹤0.01%	285
2018 Q2	$3.56M	Buy	36,200 +9,164	+34%	+$909K	0.03%	276
2018 Q1	$3.22M	Sell	27,036 -6,645	-20%	-$857K	0.02%	268
2017 Q4	$4.28M	Sell	33,681 -50,820	-60%	-$6.39M	0.03%	267
2017 Q3	$9.93M	Sell	84,501 -32,421	-28%	-$2.77M	0.07%	236
2017 Q2	$9.33M	Sell	116,922 -79,410	-40%	-$5.07M	0.07%	242
2017 Q1	$10.1M	Sell	196,332 -40,603	-17%	-$1.88M	0.07%	240
2016 Q4	$8.87M	Buy	+236,935	New	+$9.92M	0.07%	242
2015 Q4	–	Sell	-212,682	Closed	-$17.1M	–	353
2015 Q3	$17.1M	Buy	+212,682	New	+$23.6M	0.14%	208

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frontier Capital Management's ALNY Position: Q2 2026 in Review

Frontier Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.1% in Q2 2026, selling an estimated $467K and leaving 29,056 shares worth $8.75M. The position accounts for 0.08% of the portfolio, ranked #261.

Frontier Capital Management first reported a position in ALNY in Q3 2015 and has held it in 28 quarters since. The position peaked at $54.2M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Frontier Capital Management held 29,056 shares of Alnylam Pharmaceuticals worth $8.75M as of Q2 2026.
Frontier Capital Management sold 1,548 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $467K.
Alnylam Pharmaceuticals made up 0.08% of Frontier Capital Management's portfolio in Q2 2026, its #261 holding.
Frontier Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 28 quarters since.
Frontier Capital Management's Alnylam Pharmaceuticals position peaked at $54.2M in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.